Latest Insider Transactions at Spruce Biosciences, Inc. (SPRB)
This section provides a real-time view of insider transactions for Spruce Biosciences, Inc. (SPRB). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of SPRUCE BIOSCIENCES, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of SPRUCE BIOSCIENCES, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 21
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
465,021
-15.42%
|
$0
$0.75 P/Share
|
|
Mar 20
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
359,979
-10.67%
|
$0
$0.73 P/Share
|
|
Mar 19
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
593,000
-14.94%
|
$0
$0.76 P/Share
|
|
Mar 18
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
842,020
-17.51%
|
$0
$0.77 P/Share
|
|
Mar 14
2024
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
1,912,316
-28.45%
|
$0
$0.89 P/Share
|
|
Dec 29
2023
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
9,361
+14.46%
|
$0
$0.98 P/Share
|
|
Dec 29
2023
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Grant, award, or other acquisition
|
Direct |
11,255
+5.26%
|
$0
$0.98 P/Share
|
|
Dec 15
2023
|
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
38,384
-26.34%
|
$38,384
$1.66 P/Share
|
|
Dec 15
2023
|
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
111,000
+43.24%
|
-
|
|
Dec 15
2023
|
Samir M. Gharib PRESIDENT AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
36,095
-9.25%
|
$36,095
$1.66 P/Share
|
|
Dec 15
2023
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
112,250
+21.84%
|
-
|
|
Dec 15
2023
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
10,980
-19.27%
|
$10,980
$1.66 P/Share
|
|
Dec 15
2023
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
31,750
+35.78%
|
-
|
|
Jun 30
2023
|
Samir M. Gharib PRESIDENT AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
25,936
-18.36%
|
$51,872
$2.15 P/Share
|
|
Jun 30
2023
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
75,000
+34.67%
|
-
|
|
Jun 30
2023
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Grant, award, or other acquisition
|
Direct |
10,484
+13.65%
|
$0
$0.98 P/Share
|
|
Jun 30
2023
|
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+36.56%
|
$0
$0.98 P/Share
|
|
Jun 30
2023
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,378
+32.9%
|
$0
$0.98 P/Share
|
|
Feb 16
2023
|
Niall O'Donnell Director |
BUY
Open market or private purchase
|
Indirect |
630,400
+32.22%
|
$1,891,200
$3.17 P/Share
|
|
Feb 16
2023
|
Novo Holdings > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
2,208,000
+24.72%
|
$6,624,000
$3.17 P/Share
|
|
Jan 03
2023
|
Samir M. Gharib PRESIDENT AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
15,293
-21.51%
|
$15,293
$1.15 P/Share
|
|
Jan 03
2023
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+34.53%
|
-
|
|
Dec 30
2022
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Grant, award, or other acquisition
|
Direct |
1
+0.0%
|
$0
$0.93 P/Share
|
|
Dec 30
2022
|
Javier B. Szwarcberg CHIEF EXECUTIVE OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
14,705
+50.0%
|
$0
$0.93 P/Share
|
|
Dec 30
2022
|
Ralph William Charlton Iii CHIEF MEDICAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
12,864
+50.0%
|
$0
$0.93 P/Share
|
|
Jun 30
2022
|
Samir M. Gharib PRESIDENT AND CFO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,968
-27.84%
|
$12,968
$1.74 P/Share
|
|
Jun 30
2022
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Grant, award, or other acquisition
|
Direct |
5,446
+10.47%
|
$5,446
$1.48 P/Share
|
|
Jun 30
2022
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
37,500
+47.69%
|
-
|
|
Dec 31
2021
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Other acquisition or disposition
|
Direct |
2,220
+32.4%
|
$6,660
$3.79 P/Share
|
|
Jun 30
2021
|
Samir M. Gharib PRESIDENT AND CFO |
BUY
Other acquisition or disposition
|
Direct |
1,412
+50.0%
|
$12,708
$9.53 P/Share
|
|
Jun 30
2021
|
Richard King Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
2,230
+50.0%
|
$20,070
$9.53 P/Share
|
|
May 20
2021
|
Camilla V Simpson |
SELL
Open market or private sale
|
Direct |
334
-100.0%
|
$5,010
$15.29 P/Share
|
|
May 20
2021
|
Camilla V Simpson |
BUY
Exercise of conversion of derivative security
|
Direct |
334
+50.0%
|
$0
$0.85 P/Share
|
|
May 19
2021
|
Novo Holdings > 10% Shareholder |
SELL
Open market or private sale
|
Direct |
475,000
-9.52%
|
$6,175,000
$13.9 P/Share
|
|
Apr 30
2021
|
Camilla V Simpson |
SELL
Open market or private sale
|
Direct |
14,045
-100.0%
|
$224,720
$16.14 P/Share
|
|
Apr 30
2021
|
Camilla V Simpson |
BUY
Exercise of conversion of derivative security
|
Direct |
14,045
+50.0%
|
$0
$0.85 P/Share
|
|
Oct 14
2020
|
Jonas Hansson Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+10.95%
|
$3,750,000
$15.0 P/Share
|
|
Oct 14
2020
|
Jonas Hansson Director |
BUY
Conversion of derivative security
|
Indirect |
1,783,621
+50.0%
|
-
|
|
Oct 14
2020
|
Health Cap Viii, L.P. |
BUY
Open market or private purchase
|
Direct |
250,000
+10.95%
|
$3,750,000
$15.0 P/Share
|
|
Oct 14
2020
|
Health Cap Viii, L.P. |
BUY
Conversion of derivative security
|
Direct |
1,783,621
+50.0%
|
-
|
|
Oct 14
2020
|
Moghrabi Dina Chaya Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+10.37%
|
$3,750,000
$15.0 P/Share
|
|
Oct 14
2020
|
Moghrabi Dina Chaya Director |
BUY
Conversion of derivative security
|
Indirect |
1,911,022
+50.0%
|
-
|
|
Oct 14
2020
|
Omega Fund Vi, L.P. |
BUY
Open market or private purchase
|
Direct |
250,000
+10.37%
|
$3,750,000
$15.0 P/Share
|
|
Oct 14
2020
|
Omega Fund Vi, L.P. |
BUY
Conversion of derivative security
|
Direct |
1,911,022
+50.0%
|
-
|
|
Oct 14
2020
|
Niall O'Donnell Director |
BUY
Open market or private purchase
|
Indirect |
250,000
+26.43%
|
$3,750,000
$15.0 P/Share
|
|
Oct 14
2020
|
Niall O'Donnell Director |
BUY
Conversion of derivative security
|
Indirect |
445,905
+50.0%
|
-
|
|
Oct 14
2020
|
Bali Muralidhar |
BUY
Open market or private purchase
|
Indirect |
200,000
+10.04%
|
$3,000,000
$15.0 P/Share
|
|
Oct 14
2020
|
Bali Muralidhar |
BUY
Conversion of derivative security
|
Indirect |
1,592,518
+50.0%
|
-
|
|
Oct 14
2020
|
River Vest Venture Fund Iii, L.P. > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+10.42%
|
$3,750,000
$15.0 P/Share
|
|
Oct 14
2020
|
River Vest Venture Fund Iii, L.P. > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,898,281
+40.19%
|
-
|